Signing of Global Pandemic Treaty Delayed Once Again: Key Disputes Over PABS System
Negotiators miss crucial deadlines for finalizing the legally binding WHO Global Pandemic Treaty amid unresolved international disputes over pathogen genomic data sharing and equitable vaccine distribution.
1.Critical Geneva Deadline Missed as Global Consensus Stalls
International health negotiators in Geneva have once again failed to reach a finalized consensus on the landmark WHO Convention, Agreement or Other International Instrument on Pandemic Prevention, Preparedness and Response (commonly termed the Pandemic Agreement). Despite months of intense diplomatic negotiations, deep divisions between high-income pharmaceutical-manufacturing nations and low-to-middle-income countries have pushed the official timeline for ratification back toward the 2027 World Health Assembly.
2.Pathogen Access and Benefit Sharing (PABS) Remains the Core Battleground
At the epicenter of the diplomatic stalemate is Article 12 of the treaty text, governing Pathogen Access and Benefit Sharing (PABS). When a novel infectious pathogen emerges, rapid genomic sequencing and biological sample sharing by frontline countries are vital for global diagnostic and vaccine development. However, developing nations—represented by the 47-member 'Group for Equity'—argue that under past frameworks, low-income nations freely provided vital viral data only to be priced out or placed at the back of the queue when multinational pharmaceutical companies commercialized resulting vaccines and treatments.
3.The Equity Coalition vs. Western Intellectual Property Protections
The Group for Equity demands that pharmaceutical manufacturers utilizing the PABS multilateral system be legally bound to allocate at least 20% of real-time production (10% as free donations and 10% at cost-price) to the WHO during international public health emergencies. Conversely, delegations from the European Union, the United States, Switzerland, and the United Kingdom argue that rigid mandatory product quotas and intellectual property waiver clauses could stifle private investment in cutting-edge biotechnology research, advocating instead for voluntary tiered-pricing models.
4.Condemnation from Global Health Leaders and Independent Panels
The ongoing deadlock has drawn sharp criticism from the Independent Panel for Pandemic Preparedness and Response (IPPPR). Co-chairs Helen Clark (former Prime Minister of New Zealand) and Ellen Johnson Sirleaf (former President of Liberia) warned that the inability of global governments to set aside commercial and geopolitical rivalries constitutes a grave threat to international biosecurity, leaving the world vulnerable to a repeat of the catastrophic systemic failures experienced during COVID-19.
5.Countering Disinformation and Sovereignty Misconceptions
Beyond technical and commercial negotiations, the treaty process has suffered from widespread viral disinformation campaigns across digital platforms. False claims alleging that the pandemic treaty would grant the WHO sweeping powers to enforce national lockdowns, mandate universal vaccinations, or override sovereign border controls have created political friction in several parliaments. WHO legal counsels have repeatedly reiterated that Article 24 of the draft text explicitly reaffirms that public health governance remains the sovereign right and responsibility of each individual nation.
6.The Road to 2027: Rebuilding Trust in Global Public Health
WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized that the next global health crisis is an epidemiological inevitability. As regional working groups continue closed-door sessions to draft compromise language around technology transfer and emergency financing mechanisms, the coming year will test whether international multilateralism can forge an equitable, resilient defense before the next high-consequence pathogen emerges.
Frequently Asked Questions (FAQ)
Q1: What is the primary reason for the delay in signing the Global Pandemic Treaty?
The core dispute centers around Pathogen Access and Benefit Sharing (PABS). Developing nations demand legally binding guarantees for immediate access to vaccines, diagnostics, and therapeutics produced using pathogen samples they contribute, whereas developed nations and pharmaceutical stakeholders push for market-based, voluntary licensing frameworks.
Q2: When is the new target deadline for the WHO Pandemic Accord?
Following the stalled negotiations in Geneva, the Intergovernmental Negotiating Body (INB) extended the mandate with a target to finalize the draft text for formal adoption at the 2027 World Health Assembly.
Q3: Does the WHO Pandemic Treaty affect national sovereignty?
No. Official legal analysis confirms the treaty explicitly reinforces national sovereignty over domestic public health policies. Misinformation campaigns claiming the WHO would gain emergency governance powers over sovereign states have contributed to political resistance in several member nations.
Editorial Standards & Fact-Checking Transparency
This report adheres to Daily Science News' rigorous academic guidelines. All claims are verified against primary scientific literature from institutions including NASA, ESA, CERN, and peer-reviewed journals. Supervised by Dulaksha Sandeepa. Questions or corrections? Contact contact@sciencenewshub.click.